Health professionals are being
advised by the Therapeutic Goods
Administration that serious cases
of diabetic ketoacidosis (DKA)
have been reported in patients
taking prescription medicines that
are inhibitors of sodium glucose
co-transporter 2 (SGLT2), namely
canagliflozin, dapagliflozin or
empagliflozin.
For details see www.tga.gov.au.The above article was sent to subscribers in Pharmacy Daily's issue from 17 Aug 15 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 17 Aug 15
THE stark health inequalities between Australians living in regional and metro areas have been highlighted in a new report from The Royal Flying Doctor Service (RFDS).
AN “AI explosion” is sweeping Australia’s healthcare sector, signalling the arrival of an “extraordinary era of medicine”, according to a new report from CSIRO.
THE Australian and New Zealand College of Advanced Pharmacy (ANZCAP) has celebrated the 1,000th pharmacist to complete its pharmacy recognition program (PD 24 Nov 2023).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.